- New data shows long-term use of an AID system powered by Dexcom
CGM can safely maintain improvements in glycaemic outcomes for up
to two years1.
- Real-world evidence demonstrates reduction in severe
hypoglycaemia and diabetic ketoacidosis over 12 months in people
with Type 1 diabetes using a Dexcom-powered Automated Insulin
Delivery (AID) system2.
- New global user data analysis shows an association between
Dexcom CGM usage and a meaningful reduction in HbA1c for people
treating their T2D with a GLP-14.
- Dexcom continues to enhance access to its portfolio around the
world, including swift roll out of Dexcom ONE+ and the now, FDA
cleared, Direct-to-Watch feature for G7.
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time
continuous glucose monitoring (CGM) for people with diabetes,
announced compelling new clinical evidence supporting the use of
Dexcom continuous glucose monitoring (CGM) for automated insulin
delivery (AID) systems. Dexcom also announced data showcasing the
significant benefits of CGM use for individuals managing Type 2
diabetes, along with groundbreaking evidence demonstrating a direct
association between CGM use and reduced mortality in people with
Type 1 and Type 2 diabetes. The evidence and data will be presented
during Dexcom symposia and presentations at the 17th International
Conference on Advanced Technologies and Treatments for Diabetes,
held March 6-9, in Florence.
“As the pioneer in biosensing, since last year’s ATTD, Dexcom
has moved at an extraordinary pace. We launched G7 in 16 additional
countries, released Dexcom ONE+ and are today announcing the phased
launch of ‘Direct-to-watch’, that’s two best-in-class products and
a feature designed to empower even more people living with
diabetes. Globally, we’ve expanded access to Dexcom products by
over 5 million people,” said Kevin Sayer, President, CEO, and
Chairman of the Board at Dexcom.
Driving access to best-in-class CGM technology
Dexcom has continued to drive access to its pioneering real-time
CGM technology, launching its best-in-class G7 sensor in 16 new
markets since ATTD 2023. The company’s latest sensor, Dexcom ONE+,
which was built based on user and HCP feedback and is designed to
be easy to use for anyone living with diabetes, also recently
launched in four European markets.
Delivering exceptional end-user experiences with direct
connectivity to Apple Watch
Showing a commitment to not only expanding access to
life-changing CGM but also to improving the experience for those
already using Dexcom CGM, Dexcom announced that ‘direct to Apple
Watch’ functionality for Apple Watch will begin a phased launch
available to all G7 iOS users in the second quarter of this year.
The announcement means that Dexcom G7 will soon be the only CGM
system that can connect directly to Apple Watch without always
needing to carry an iPhone.† People choosing Dexcom G7 to help
manage their diabetes will have access to ‘direct to Apple Watch’
as soon as it launches in their country.
Unparalleled AID abilities
With robust clinical evidence and strong partner relationships,
Dexcom’s pioneering leadership and capabilities within connected
systems remains unparalleled. Of particular significance within AID
systems, the clinically meaningful health outcomes resulting from
use of both the Tandem t:slim X2 insulin pump with Control-IQ
technology and Insulet Omnipod 5 are only proven when powered by
Dexcom CGM. Further demonstrating the value of AID systems powered
by Dexcom CGM, Dexcom will showcase recently published evidence at
ATTD 2024. Data from the longest prospective follow-up study to
date of a cohort with established Type 1 diabetes1, using the
Insulet Omnipod 5 automated insulin delivery system with Dexcom G6,
showed that long-term use of the AID system could safely maintain
improvements in glycaemic outcomes for up to two years. Perhaps
most significantly, despite the long duration of the study, event
rates for severe hypoglycaemia and diabetic ketoacidosis remained
low at 2.04 and 0.24 events per 100 person-years.
Furthermore, real-world evidence from almost 3,000 people using
a Tandem Control-IQ AID system, powered by Dexcom CGM, demonstrated
lower rates for both severe hypoglycaemia and diabetic ketoacidosis
over 12 months compared to historic rates2. Concurrent with these
lower rates, on average adult participants spent more than 70% CGM
time in range, while paediatric participants achieved 60% CGM time
in range.
In December, Dexcom and Tandem announced the connection of
Dexcom G7 to Tandem’s t:slim X2 insulin pump software in the USA,
swiftly followed by a roll out in markets across Europe, and in
both South Africa and New Zealand. The announcement marked a
powerful alliance combining Dexcom’s best-in-class G7 sensor with
Tandem’s most widely available pump system.
Dexcom also announced the availability, in the USA, of Dexcom G6
with Tandem Mobi, the world’s smallest, durable automated insulin
delivery system++. Integration with Dexcom G7 will quickly follow
in the USA in the second quarter of this year.
Exceptionally effective CGM for all types of diabetes
As demonstrated in multiple symposia and presentations at ATTD
this year, clinical evidence continues to build demonstrating the
effectiveness of Dexcom CGM use amongst people with all types of
diabetes. Of particular note, Dexcom announced a first-of-its-kind
study directly linking the benefits of CGM with a reduction in
mortality for people treating Type 1 or Type 2 diabetes with
insulin‡3. These results indicate use of CGM may have broad-based
benefits that extend beyond glucose lowering in patients with
diabetes on insulin.
Dexcom also unveiled new global user data analysis showing
clinically meaningful reduction in HbA1c specifically for people
managing their Type 2 diabetes with a GLP1 and using a CGM sensor
compared to groups not using CGM*4. Dexcom data also showed that
amongst Type 2 user populations, the more regularly a Dexcom CGM
was worn, the more time a user spent within their desired glucose
range5. Furthermore, a qualitative study involving people treating
their Type 2 diabetes with basal insulin found the visualisation of
glucose levels offered by Dexcom CGM improved understanding of the
impact of treatment and lifestyle decisions on glucose levels, and
the impact of those glucose levels on additional health
issues6.
“The breadth of studies and outcomes showcased here at ATTD
demonstrates the crucial role that Dexcom CGM can play in the
treatment of Type 2 diabetes,” said Dr Thomas Grace, MD, Head of
Clinical Advocacy and Outcomes at Dexcom. “From demonstrating a
clinically significant decrease in HbA1c to increasing time in
range and generally improving well-being, the results speak for
themselves. We also continue to see studies confirm that whilst
GLP1s are an effective initial treatment for those living with Type
2 diabetes the use of Dexcom CGM can strengthen their impact and
provide an alternative for sustained long-term metabolic health
improvement.”
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health
through innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, Calif., and with operations across
Europe and select parts of Asia/Oceania, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers, and providers, Dexcom works to simplify and
improve diabetes management around the world. For more information
on Dexcom, visit www.dexcom.com.
†Compatible smartphone is required to pair a new Dexcom G7
sensor with an Apple Watch. Dexcom G7 users must continuously have
their smartphone within 20 feet / 6 meters to utilize the
Share/Follow features. Apple Watch is not capable of Share/Follow.
* Any insulin: CGM (-0.64%) vs control (-0.25%), p<0.0001. NIT:
(-0.63%) CGM vs control (-0.14%), p<0.0001 ++ As of Feb., 2024.
Data on file, Tandem Diabetes Care. ‡ Risk for mortality was
significantly lower in both T1D CGM users (Hazard Ratio: 0.53,
CI:-0.43-0.65) and T2D CGM users (HR 0.86, CI: 0.76-0.97) than in
non-users over 18 months
1 Criego A B et al. Two Years with a Tubeless Automated Insulin
Delivery System:A Single-Arm Multicenter Trial in Children,
Adolescents, and Adults with Type 1 Diabetes. Diabetes Technology
and Therapeutics. 2024. 26(2) 2 Graham, R et al. Real-World Use of
Control-IQ Technology is Associated with a Lower Rate of Severe
Hypoglycemia and Diabetic Ketoacidosis Than Historical Data:
Results of the Control-IQ Observational (CLIO) Prospective Study
Diabetes Technology and Therapeutics. 2024. 26(2). 3. Reaven, P.
Initiating Continuous Glucose Monitoring (CGM) in Adult-Onset Type
1 and Type 2 Diabetes Reduces Mortality. Presented at ATTD, 2024;
March 9th. Florence, Italy. 4 Nemlekar, P. Association between
Change in HbA1c and Continuous Glucose Monitor (CGM) Use in
Patients with Type 2 Diabetes (PWT2D) using Glucagon-Like Peptide-1
Receptor Agonists (GLP1-RA) Presented at ATTD Conference March
2024. 5 Crawford, M Greater Time-in-Range (TIR) When CGM Gaps Are
Shorter For People With Type 2 Diabetes: Different Approaches to
Analyzing Gaps in CGM Wear From Real-World Data Presented at ATTD
Conference March 2024. 6 Crawford, M Value of CGM in Medication
Titration, Comorbidity Management, and Therapy Engagement: A
Qualitative Study of T2D Basal Insulin Users Presented at ATTD
Conference March 2024.
Dexcom Symposia Overview – 2024
Dexcom Innovation: AID, Smart Devices and EHR Integration for
Enhanced Care
Wednesday, March 6, 2024, 2:40 – 4:10 PM CET, in Hall C
Moderated by Professor Parth Kar, MD
- This expert panel will speak to the latest on automated insulin
delivery (AID), connected smart devices and electronic health
record (EHR) integrations. We will shed light on the latest
innovations with Dexcom CGM and the evidence expanding AID
opportunities for people living with type 1 diabetes, including
pregnant women. Additionally, we will discuss late breaking
evidence highlighting improved outcomes with Dexcom-powered AID
systems. We’ll also share the latest advancements in the product
pipeline focused on improving the patient experience and glycemic
outcomes with integrated diabetes technologies. Finally, we will
highlight recent developments with Dexcom’s direct integration into
the EHR designed to improve workflow and enable healthcare
professionals to enhance patient interactions and care.
Dexcom Breakthroughs: Leveraging CGM Early and Across the
Spectrum of Type 2 Diabetes Care
Thursday, March 7, 2024, 2:40 – 4:10 PM CET, in Hall A
Moderated by Sufyan Hussain, MD
- Dexcom has led the development of evidence to support the use
of Dexcom CGM in people with type 2 diabetes, highlighting the role
of CGM for early glycemic goal achievement for effective T2D
management. In this session you’ll be the first to learn about
Dexcom’s newest system, Dexcom ONE+! We’ll dive into compelling
data illustrating Dexcom's pivotal role in optimizing outcomes for
individuals across the T2D spectrum and the profound influence on
enhancing glycemic management. We’ll expand the journey to include
an examination of time in tight range, exploring the nuanced
understanding of the metric. Additionally, we’ll explore data
demonstrating the synergistic effects of Dexcom CGM combined with
GLP-1 receptor agonists, shedding light on how the combination
contributes to a comprehensive approach to care. Dexcom has a
multifaceted role in early intervention and personalized strategies
for T2D.
Dexcom Transformation: Improving Lives of People with Type 2
Diabetes
Friday, March 8, 2024, 8:30 – 9:20 AM CET, in Hall C
Moderated by William H. Polonsky, MD, PhD
- Explore the cutting-edge of CGM technology with Dexcom,
featuring a comprehensive portfolio of CGM products including the
new Dexcom ONE+ system. Join a dynamic conversation, moderated by
Dr. William Polonsky, PhD, CDCES, as experts delve into the
transformative impact of real-time CGM for people with type 2
diabetes. Uncover a dual perspective, examining both the attainment
of clinical goals as well as qualitative, patient-reported outcomes
that spotlight how individuals leverage Dexcom CGM to successfully
understand the impact of lifestyle choices that help inform
personalized diabetes management goals.
For more information about these presentations and to
register to virtually attend the conference, visit
https://attd.kenes.com/.
Category: IR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240305323546/en/
Media Contact Gemma McDonald
+44 (0) 7552 368398 gemma.mcdonald@dexcom.com
Investor Contact Sean
Christensen 858-203-6657 sean.christensen@dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Apr 2023 to Apr 2024
